Investigation of the Association Between Metabolic Biomarkers and Neurophysiological Findings in Idiopathic Sensorimotor Polyneuropathy
Abstract
Objective: This study aimed to evaluate the association between atherogenic lipid indices—namely the Atherogenic Index of Plasma (AIP), TG/HDL, and LDL/HDL ratios—and electrophysiological findings in patients with idiopathic sensorimotor polyneuropathy, and to determine the clinical utility of these parameters in assessing disease severity.
Methods: This retrospective cross-sectional study included patients diagnosed with idiopathic sensorimotor polyneuropathy based on electrophysiological examination (EMG). Neuropathy severity was classified as mild, moderate, or severe according to electrophysiological findings. AIP, TG/HDL-C, and LDL/HDL-C ratios were also analyzed. Statistical comparisons were performed using appropriate parametric or nonparametric tests, and a p-value <0.05 was considered statistically significant.
Results: A total of 304 patients were included and classified according to EMG severity as mild (n=72), moderate (n=101), and severe (n=131). Demographic characteristics were similar among the groups (p>0.05). HDL-cholesterol levels decreased significantly with increasing neuropathy severity (p<0.001), whereas triglyceride levels, TG/HDL-C and LDL/HDL-C ratios, and the Atherogenic Index of Plasma increased progressively across the severity groups (all p<0.05).
Conclusion: Atherogenic lipid indices, particularly the AIP, TG/HDL-C, and LDL/HDL-C ratios, were significantly associated with electrophysiological severity in patients with idiopathic sensorimotor polyneuropathy. These findings suggest that atherogenic dyslipidemia may contribute to peripheral nerve damage and that these readily available metabolic indices may serve as potential biomarkers of disease severity.
Keywords
Polyneuropathy, inflammation, atherogenic index
Project Number
Ethical Statement
References
- Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016;31(1):5-20. doi:10.1007/s10654-015-0094-6.
- Pasnoor M, Nascimento OJM, Trivedi J, Wolfe GI, Nations S, Herbelin L, et al. North America and South America (NA-SA) neuropathy project. Int J Neurosci. 2013;123(8):563-7. doi: 10.3109/00207454.2013.782026.
- Mirian A, Aljohani Z, Grushka D, Florendo-Cumbermack A. Diagnosis and management of patients with polyneuropathy. CMAJ. 2023;195(6):E227-33. doi:10.1503/cmaj.220936.
- Yıldırım A, Avcı HK, Güngen BD, Yağız O, Saçak Ş, Polat H. Tip 2 diyabetes mellitus tanılı hastalarda HbA1c seviyesi ile distal simetrik polinöropati şiddeti arasındaki ilişki. Istanbul Med J. 2014;15(3):175-7. doi:10.5152/imj.2014.98853.
- Babic N, Valjevac A, Zaciragic A, Avdagic N, Zukic S, Hasic S. The triglyceride/HDL ratio and triglyceride glucose index as predictors of glycemic control in patients with diabetes mellitus type 2. Med Arch. 2019;73(3):163-8. doi:10.5455/medarh.2019.73.163-168.
- Wang L, Chen F, Chai X, Chen Y, Li Z. Atherogenic index of plasma is an independent risk factor for coronary artery disease and a higher SYNTAX score. Angiology. 2021;72(2):181-6. doi:10.1177/0003319720949804.
- Eid SA, Rumora AE, Beirowski B, Bennett DL, Hur J, Savelieff MG, et al. New perspectives in diabetic neuropathy. Neuron. 2023;111(17):2623-41. doi:10.1016/j.neuron.2023.05.003.
- Callaghan BC, Hur J, Feldman EL. Diabetic neuropathy: one disease or two? Curr Opin Neurol. 2012;25(5):536-41. doi:10.1097/WCO.0b013e328357a797.
- Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AAF, Feldman EL. Elevated triglycerides correlate with the progression of diabetic neuropathy. Diabetes. 2009;58(7):1634-40. doi:10.2337/db08-1771.
- Nienov OH, Matte L, Dias LS, Schmid H. Peripheral polyneuropathy in severely obese patients with metabolic syndrome but without diabetes: association with low HDL-cholesterol. Rev Assoc Med Bras (1992). 2017;63(4):324-31. doi:10.1590/1806-9282.63.04.324.